Join us for a 4-hour live MOUD training webcast that offers credits applicable toward the 8-hour DEA training requirement. This session awards 4 hours of participation credit, which can be applied toward the 8-hour DEA requirement. (Additional training hours are available for those needing to fulfill the full 8-hour DEA requirement- more information below). Open to all medical professionals and students.

Details:

• Date and Time: Starts at 8:00 AM Eastern Time (please check your time zone)
• Platform: Zoom (download Zoom app here: Zoom)
• Credits: 1A AOA CME and AAFP CME available

IMPORTANT: AOAAM cannot verify phone-only participation. In order to receive credit, the participant must be online, both viewing and listening to the presentation (in its entirety of 4-hours) and participating in any interactive polling questions or case studies that may be presented. Partial participation will not be awarded. 

Prepare for an informative session that advances your qualifications and fulfills important professional requirements!

Need additional hours after this 4-credit MOUD training session?:

AOAAM offers a range of 1-hour On-Demand training modules to help you complete the 8-hour DEA training requirement. Choose from a variety of HOT Topics (look for the ORN icon), complete each module, and download your certificate after each session. Retain these certificates, along with the certificate from this 4-hour webinar, to achieve a combined total of 8 training hours. CME: 1 AMA PRA Category 1 available / 1 AOA Category 1A available.

Start your additional training here: AOAAM ORN On-Demand Training

• To understand the federal Drug Abuse Treatment Act (DATA) of 2000 and the subsequent revisions that lists the criteria needed for Office Based Opioid Treatment (OBOT) utilizing buprenorphine for opioid dependence and the new changes/guidelines
• To distinguish between spontaneous withdrawal and precipitated withdrawal and the appropriate methods of buprenorphine induction
• To describe and contrast the functions of full mu agonists, partial agonists and antagonists
• To describe the basic approach used in at least three different types of non-pharmacological treatment of opioid dependence
• To describe three symptoms of opioid withdrawal or intoxication that mimic symptoms of a psychiatric disorder
• To list the criteria for establishing the diagnosis of opioid dependence
• To list at least three situations in which patient information, with patient identity, can be shared under current laws protecting the patient’s confidentiality
• To understand and minimize buprenorphine misuse and diversion. To be aware of the issues of drug interactions of buprenorphine and pediatric exposures

This course has been reviewed and is acceptable for 4 credits of AOA Category 1A by the AOA CCME. It has also been reviewed and is acceptable for 4 Prescribed credit(s) by the American Academy of Family Physicians.

Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed credit, not as Category 1.

 

Stephen A. Wyatt, D.O, is a Board-Certified Psychiatrist with added subspecialty certification in Addiction Psychiatry. He is the Addiction Psychiatry Fellowship Director at MAHEC in Asheville, NC. He completed a NIDA clinical research fellowship in addiction psychiatry at the Yale School of Medicine. He is an adjunct clinical faculty member of the University of North Carolina and the Director of the Addiction Psychiatry Fellowship at MAHEC. He is a past president of the AOAAM.  He is the current Chairman of the NC Psychiatric Asso. Addiction Psychiatry Committee and the Vice Chair of the Coalition on Physician Education in Substance Use Disorders a national organization focused on addiction medicine medical school education. He was the Co-Chair for the 2020 focused update of the ASAM Clinical Guidelines for Office Based Opioid Treatment. He is a clinical expert for the SAMHSA funded Provider Clinical Support System, PCSS; Medication Assisted Treatment and Implementation Projects.

 

 

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent and obtain a waiver to your DEA license to prescribe schedule III-V medications, approved by the FDA for the treatment of opioid use disorder (OUD). The Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners on the treatment and management of patients with opioid or other substance use disorders. Beginning on June 27, 2023, practitioners will be required to check a box on their online DEA registration form, affirming that they have completed the new training requirement.

Funding for this initiative was made possible (in part) by grant nos. 1H79TI086770 and 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.